Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Non Operating Income: 2019-2024

Historic Non Operating Income for Intellia Therapeutics (NTLA) over the last 6 years, with Dec 2024 value amounting to $15.2 million.

  • Intellia Therapeutics' Non Operating Income rose 12.09% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.9 million, marking a year-over-year increase of 113.44%. This contributed to the annual value of $15.2 million for FY2024, which is 55.30% down from last year.
  • According to the latest figures from FY2024, Intellia Therapeutics' Non Operating Income is $15.2 million, which was down 55.30% from $34.1 million recorded in FY2023.
  • Intellia Therapeutics' 5-year Non Operating Income high stood at $34.1 million for FY2023, and its period low was -$16.0 million during FY2022.
  • For the 3-year period, Intellia Therapeutics' Non Operating Income averaged around $11.1 million, with its median value being $15.2 million (2024).
  • Its Non Operating Income has fluctuated over the past 5 years, first tumbled by 38,047.62% in 2022, then skyrocketed by 312.83% in 2023.
  • Over the past 5 years, Intellia Therapeutics' Non Operating Income (Yearly) stood at $2.4 million in 2020, then plummeted by 101.79% to -$42,000 in 2021, then plummeted by 38,047.62% to -$16.0 million in 2022, then spiked by 312.83% to $34.1 million in 2023, then plummeted by 55.30% to $15.2 million in 2024.